Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
Sign Up to like & getrecommendations! Published in 2019 at "The Lancet"
DOI: 10.1016/s0140-6736(19)31271-1
Abstract: BACKGROUND Glucagon-like peptide-1 (GLP-1) receptor agonists are effective treatments for type 2 diabetes, lowering glycated haemoglobin (HbA1c) and weight, but are currently only approved for use as subcutaneous injections. Oral semaglutide, a novel GLP-1 agonist,… read more here.
Keywords: oral semaglutide; placebo; subcutaneous liraglutide; week ... See more keywords
An Increase of Heart Rate and Electrocardiographic Changes after Subcutaneous Liraglutide
Sign Up to like & getrecommendations! Published in 2017 at "Chinese Medical Journal"
DOI: 10.4103/0366-6999.219142
Abstract: To the Editor: Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome results (LEADER) trial illustrated that among patients with type 2 diabetes mellitus, those in the liraglutide group had lower rates of cardiovascular… read more here.
Keywords: electrocardiographic changes; rate electrocardiographic; subcutaneous liraglutide; increase heart ... See more keywords